Guangzhou BeBetter Medicine Technology has signed a collaborative research agreement with  Taiwan 's PharmaEngine to develop new chemical entities that address predefined oncology targets. BeBetter will own  China  rights to any discoveries, while PharmaEngine will be able to market the products in the rest of the world. BeBetter will undertake discovery of optimized NCEs for IND-enabling studies. PharmaEngine will be responsible for their development and commercialization. More details.... Stock Symbol: (TWO: 4162) Share this with colleagues: // //